Background: Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, has an unfavorable prognosis. ABCA4 has been identified as an oncogene in multiple malignancies, but its specific mechanisms in LUAD remain poorly understood. This study aims to explore the function of ABCA4 in LUAD with a focus on mitophagy. Methods: ABCA4 expression in LUAD was evaluated using the TCGA database, western blotting, RT-qPCR, and immunohistochemistry. The effects of ABCA4 knockdown on LUAD progression were examined in vitro (CCK8, Muse (R) Cell Analyzer, Transwell), and in vivo through (xenogeneic tumor experiments). Mitophagy was assessed by JC-1, TMRE, and DCFH-DA staining, the Muse Oxidative Stress Kit, transmission electron microscopy, and western blotting. Chloroquine (CQ) and S7306 were applied in rescue experiment. RNA-seq identified differentially expressed genes (DEGs) after siABCA4 treatment, and the effects of ABCA4 on LUAD by modulating TMSB4X were explored. Results: ABCA4 was up-regulated in the TCGA database, LUAD tissues, and cell lines. ABCA4 knockdown inhibited proliferation and tumor growth while promoting apoptosis and mitophagy. Mechanistically, siABCA4 increased AMPK phosphorylation levels. CQ or S7306 partially reversed these biological effects. Additionally, ABCA4 may interact with TMSB4X to regulate mitophagy via the AMPK pathway, thereby influencing LUAD progression. Conclusions: ABCA4 was overexpressed in LUAD, and its knockdown might promote mitophagy in LUAD progression via the AMPK pathway by modulating TMSB4X, suggesting that ABCA4 could serve as a therapeutic target for LUAD patients.
基金:
Applied Basic Research Foundation of Yunnan Province (CN) [2017FE468 (-125), 202001AY070001-111]; Open Project of the Clinical Medicine Center of the First People's Hospital of Yunnan Province [2021LCZXXF-XY12]; CAMS Innovation Fund for Medical Sciences (ClFMS) [2016-12M-3-024]; Yunnan Province Clinical Research Center for Hematologic Disease [2022LCZXKF-XY04]; Yunnan Province Clinical Research Center for Hematologic Disease [2023YZX-XY02]; Kunming University of Science and Technology & the First People's Hospital of Yunnan Province Joint Special Project on Medical Research [KUST-KH2022028Y]; Yunnan Fundamental Research Projects [202401AY070001109]; Science and technology plan project of Yunnan Province [202403AC100017]; Open Research of Key Laboratory of Innovative Application of Characteristic Traditional Chinese Medicine in Yunnan Province [2024ZYZDKFKT-05]; Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment
第一作者机构:[1]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Xian 710061, Shaanxi, Peoples R China[2]First Peoples Hosp Yunnan Prov, Dept Blood Transfus, Kunming 650032, Yunnan, Peoples R China[3]Kunming Univ Sci & Technol, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China
通讯作者:
通讯机构:[1]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, Xian 710061, Shaanxi, Peoples R China[*1]277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China
推荐引用方式(GB/T 7714):
Zhang Chan,Li Qi,Cheng Yujing,et al.ABCA4 regulates mitophagy in lung adenocarcinoma progression via AMPK pathway by modulating TMSB4X[J].INTERNATIONAL IMMUNOPHARMACOLOGY.2025,163:doi:10.1016/j.intimp.2025.115305.
APA:
Zhang, Chan,Li, Qi,Cheng, Yujing,Yang, Xin,Chen, Wanlu...&Chen, Mingwei.(2025).ABCA4 regulates mitophagy in lung adenocarcinoma progression via AMPK pathway by modulating TMSB4X.INTERNATIONAL IMMUNOPHARMACOLOGY,163,
MLA:
Zhang, Chan,et al."ABCA4 regulates mitophagy in lung adenocarcinoma progression via AMPK pathway by modulating TMSB4X".INTERNATIONAL IMMUNOPHARMACOLOGY 163.(2025)